A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

NCT00343187 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of enrollment

Conditions

Rash
Non-small-Cell Lung Cancer

Interventions

DRUG: ACZONE (dapsone) Gel, 5%
DRUG: Vehicle Control

Sponsor

Allergan